[HPV vaccination].
Human Papilloma Viruses are associated with genital carcinoma (of the cervix, anus, vulva, vagina and the penis) as well as with non-genital carcinoma (oropharyngeal carcinoma) and genital warts. In Switzerland two highly efficient and safe vaccines are available. The safety of these vaccines has been repeatedly subject of controversial discussions, however so far post marketing surveillance has always been able to confirm the safety. In Switzerland girls and young women have been offered the HPV vaccination within cantonal programmes since 2008. 2015 the recommendation for the HPV-vaccination for boys and young men was issued, and starting July 1, 2016 they as well will be offered vaccination free of charge within the cantonal programmes. This article discusses the burden of disease, efficacy and safety of the vaccines and presents facts which are important for vaccinating these young people. Specifically, aspects of the decisional capacity of adolescents to consent to the vaccination are presented. Finally, the future perspective with a focus on a new vaccine with an enlarged spectrum of HPV-types is discussed.
1 Dr. med. Susanne Stronski Huwiler, Fachärztin für Kinder und Jugendliche, MPH, Bern.
Susanne
S
Stronski Huwiler
2 Abteilung Übertragbare Krankheiten, Sektion Impfempfehlungen und Bekämpfungsmassnahmen, Bundesamt für Gesundheit BAG, Bern.
Anne
A
Spaar
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D006801:Humans; D057828:Informed Consent By Minors; D008297:Male; D009959:Oropharyngeal Neoplasms / Q000517:prevention & control*; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D013557:Switzerland; D014565:Urogenital Neoplasms / Q000276:immunology / Q000517:prevention & control*; D055815:Young Adult
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines; C510352:human papillomavirus vaccine, L1 type 16, 18